In 2016, limited access to imported medical cannabis products became legal. Since then, regulations have slowly evolved, expanding from allowing only imported finished products to allowing for domestic cannabis product manufacture. As of this March, more than 100,000 approvals have been granted for patients to obtain medical cannabis products, with approvals ramping up each month. And, that same month, in response to a Senate inquiry into “current barriers to patient access to medicinal cannabis in Australia,” the Australian government promised change.
As local production and R&D begins to take root, so, too, are conversations about broader reforms. Last year, the Parliament of Victoria, Australia launched a formal inquiry on cannabis, and, as Cannabis Wire recently reported, hearings are ongoing, with one planned for the town of Beechworth this week. At launch, MP Fiona Patten said, “We’re interested in hearing people’s views on whether use of cannabis should remain legal for medical treatment only or whether current restrictions on use of cannabis should be changed.”
Against this backdrop, last month, Australia’s Therapeutic Goods Administration (TGA), along with Medicinal Cannabis Industry Australia (MCIA) and Source Certain International (SCI), hosted a webinar on “medicinal cannabis advertising compliance.”
Continue reading below.
Note: Enter email for access to article